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IPSCs, a Promising Tool to Restore Muscle Atrophy 
 
As life expectancy in developed countries rises, the number of elderly persons steadily climbs 
on the way to form 12% of the population in 2050. A major problem of demographic ageing is 
sarcopenia, i.e., age-related loss of muscle mass leading to functional impairment. Roughly 5–
13% of people aged 60–70 years and 11–50% of those aged 80þ suffer sarcopenia (Landi et 
al., 2012), which is a main determinant of frailty syndrome. The latter is linked to falls, disability, 
dependence, hospitalization, and mortality, generating considerable healthcare, and social 
costs (Landi et al., 2012; Mohler et al., 2014). Although pharmacologic approaches have been 
proposed to combat sarcopenia, these are not without potential risks and secondary effects 
(Sanchis-Gomar et al., 2014). A potential alternative is regenerative medicine, whose goal is 
tissue repair/substitution with transplanted healthy tissue, e.g., embryonic stem (ES) cells from 
the same individual or a compatible donor. Yet numerous ethical and legal issues have been 
associated with the use of ES cells which has led to a breakthrough in the form of induced 
pluripotent stem cells (iPSCs) (Sommer and Mostoslavsky, 2013). iPSCs have the capacity to 
differentiate into patient specific cell types, therefore reducing the likelihood of immunological 
rejection. Since the first report by Nobel Prize laureate Yamanaka that iPSCs could be 
generated from fibroblasts through the introduction of specific transcription factors using 
retroviral systems (Takahashi and Yamanaka, 2006; Takahashi et al., 2007), more effective, 
non-integrative techniques involving the use of Sendai virus have been described (Lieu et al., 
2013). Thus, it is currently possible to generate iPSCs from a person’s somatic cells and 
differentiate them into the required functional cell type (Wilson and Wu, 2015): notably, a first 
human clinical trial is using iPSC-derived retinal pigment epithelium cells to evaluate their 
efficacy in treating macular degeneration (Reardon and Cyranoski, 2014). Further, senescent 
and centenarians’ iPSCs can re-differentiate into fully rejuvenated cells (Lapasset et al., 2011). 
These results provide strong insights into the potential of iPSCs in anti-aging regenerative 
medicine. The large size of muscles and their homogeneous structure, compared with other 
organs, make them a suitable target for iPSCs therapies. The skeletal-muscle tissue is mainly 
composed by post-mitotic cells, and the only ones which are able to proliferate and thus to 
promote tissue repair over life, the satellite cells, become scarce and dysfunctional as we age. 
Thus, because sarcopenia is a naturally occurring event independent from genomic alterations, 
differentiation of human iPSCs into rejuvenated satellite cells could be used as an autologous 
therapy against this condition. On the other hand, direct reprogramming of adult fibroblasts to a 
pluripotent state has opened new possibilities for the generation of patient- and disease-specific 
iPSCs. In this regard, the skeletal-muscle tissue is frequently deteriorated in inherited 
neurometabolic diseases. Probably owing to the rare nature of most of these disorders, 
research efforts are still insufficient. The newly available tools of genomic edition like the 
CRISPR/CAS9 system could be potentially applied to cure these conditions since the sole 
edition of the specific genetic alteration in the iPSCs followed by differentiation and cell 
engraftment could reverse, at least partially, the genetic defect in question (Huang et al., 2015; 
Song et al., 2015). Darabi et al. (2011) showed that transplantation of iPSCs-derived myogenic 
progenitors into dystrophic mice resulted in extensive engraftment, which was accompanied by 
improved contractility of treated muscles. In summary, based on the recent advances, we 
highlight the potentiality of iPSCs for treating muscle-affecting conditions for which no effective 
cure is yet available, notably aging sarcopenia but also inherited neurometabolic disorders. Both 
conditions share common pathways related to senescence and satellite cell loss or dysfunction. 
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